<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DACFE0A-574B-45B4-8769-DB2F6323373A"><gtr:id>2DACFE0A-574B-45B4-8769-DB2F6323373A</gtr:id><gtr:name>Zilico Limited</gtr:name><gtr:address><gtr:line1>The MedTECH Centre
Rutherford House
Pencroft Way
Manchester Science Park</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M15 6SZ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DACFE0A-574B-45B4-8769-DB2F6323373A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2DACFE0A-574B-45B4-8769-DB2F6323373A</gtr:id><gtr:name>Zilico Limited</gtr:name><gtr:address><gtr:line1>The MedTECH Centre
Rutherford House
Pencroft Way
Manchester Science Park</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M15 6SZ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>102693.0</gtr:offerGrant><gtr:projectCost>136924.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/41E5B8D1-D6BA-4581-9E31-CB8C5FC82B90"><gtr:id>41E5B8D1-D6BA-4581-9E31-CB8C5FC82B90</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Highfield</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131717"><gtr:id>B61A0F3C-76A2-41DC-8C51-F94FBFE9228D</gtr:id><gtr:title>Electrical Impedance Spectroscopy to detect neoplastic oral lesions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131717</gtr:grantReference><gtr:abstractText>When found at early stages of development, oral cancers have an 80 - 90 % survival rate. Unfortunately, the majority are found as late stage cancers. This accounts for the very high death rate of ~43% at five years from diagnosis, for all stages combined at time of diagnosis. Zilico Ltd is developing the next generation of cancer diagnostics and proposes to use electrical impedance spectroscopy as a tool to diagnose the presence of oral cancer.</gtr:abstractText><gtr:fund><gtr:end>2015-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>102693</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131717</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>